Prof Peter Albers speaks to ecancer about the interim analysis of mortality results after 6.5 years of follow-up of the Stockholm3 prostate cancer screening trial (STHLM3).

Prof Albers says that the STHLM3 trial utilised a single prostate-specific antigen (PSA) and Stockholm3 test to identify Gleason score ≥7 prostate cancer. In this follow-up prostate cancer specific and all-cause mortality in men invited to STHLM3 to men not invited was compared.

The results from this study might suggest a potential effect on reducing prostate cancer mortality by a single intensive screening intervention using PSA and Stockholm3 in combination, to the cost of increasing prostate cancer incidence.

Prof Albers concludes by discussing the impact of these results on clinical practice.